Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Evidence of a causal relationship between genetic tendency to gain muscle mass and uterine leiomyomata

View ORCID ProfileEeva Sliz, View ORCID ProfileJaakko Tyrmi, Nilufer Rahmioglu, Krina T. Zondervan, Christian M. Becker, FinnGen, Outi Uimari, Johannes Kettunen
doi: https://doi.org/10.1101/2021.08.20.21262098
Eeva Sliz
1Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Finland
2Biocenter Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eeva Sliz
  • For correspondence: eeva.sliz@oulu.fi
Jaakko Tyrmi
1Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Finland
2Biocenter Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jaakko Tyrmi
Nilufer Rahmioglu
6Oxford Endometriosis CaRe Centre, Nuffield Department of Women’s and Reproductive Health, University of Oxford, UK
7Wellcome Centre for Human Genetics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krina T. Zondervan
6Oxford Endometriosis CaRe Centre, Nuffield Department of Women’s and Reproductive Health, University of Oxford, UK
7Wellcome Centre for Human Genetics, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian M. Becker
6Oxford Endometriosis CaRe Centre, Nuffield Department of Women’s and Reproductive Health, University of Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FinnGen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Outi Uimari
3Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
4PEDEGO Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland
5Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Kettunen
1Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Finland
2Biocenter Oulu, Oulu, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Uterine leiomyomata (UL) are the most common benign tumours of the female genital tract with an estimated lifetime incidence of up to 70%1. To date, 7 genome-wide association studies (GWASs) have identified 35 loci predisposing to UL. To improve the understanding of the underlying genetic pathways, we conducted the largest genetic association study of UL to date in 426,558 European women from FinnGen and a previously published UL meta-GWAS2. We identified 36 novel and replicated 31 previously reported loci. Annotations of the potential candidate genes suggest involvement of smooth muscle cell (SMC) differentiation and/or proliferation-regulating genes in modulating UL risk. Our results further advocate that genetic predisposition to increased fat-free mass may be causally related to UL risk, underscoring the involvement of altered muscle tissue biology in UL pathophysiology. Overall, our findings provide novel insights into genetic risk factors related to UL, which may aid in developing novel treatment strategies.

Competing Interest Statement

KTZ: Competing financial interests: Scientific collaborations (grant funding) with Bayer AG, Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Competing non-financial interests: Board memberships of the World Endometriosis Society, World Endometriosis Research Foundation, and research advisory committee member of Wellbeing of Women UK. CMB: Competing financial interests: Scientific collaborations (grant funding) with Bayer AG, Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Scientific board Myovant; IDDM Member ObsEva. Competing non-financial interests: Chair ESHRE Endometriosis Guideline Development Group.

Funding Statement

The work was supported through The Sigrid Juselius Foundation (JK) and funds from the Academy of Finland [grant numbers 297338 and 307247](JK), Novo Nordisk Foundation [grant number NNF17OC0026062] (JK), and The Finnish Medical Association (OU). The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sarl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech Inc). Following biobanks are acknowledged for delivering biobank samples to Finngen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). All Finnish Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi). This research has been conducted using data from UK Biobank, a major biomedical database, (http://www.ukbiobank.ac.uk/) under project ID 9637 (Gallagher et al., 2019). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The FinnGen study is approved by Finnish Institute for Health and Welfare (THL), approval number THL/2031/6.02.00/2017, amendments THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3 the Social Insurance Institution (KELA) KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, and Statistics Finland TK-53-1041-17. The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 5 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Summary statistics will be made available through the NHGRI-EBI GWAS Catalog with GCSTxxxxxxx upon publication.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted August 25, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evidence of a causal relationship between genetic tendency to gain muscle mass and uterine leiomyomata
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evidence of a causal relationship between genetic tendency to gain muscle mass and uterine leiomyomata
Eeva Sliz, Jaakko Tyrmi, Nilufer Rahmioglu, Krina T. Zondervan, Christian M. Becker, FinnGen, Outi Uimari, Johannes Kettunen
medRxiv 2021.08.20.21262098; doi: https://doi.org/10.1101/2021.08.20.21262098
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evidence of a causal relationship between genetic tendency to gain muscle mass and uterine leiomyomata
Eeva Sliz, Jaakko Tyrmi, Nilufer Rahmioglu, Krina T. Zondervan, Christian M. Becker, FinnGen, Outi Uimari, Johannes Kettunen
medRxiv 2021.08.20.21262098; doi: https://doi.org/10.1101/2021.08.20.21262098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Genetic and Genomic Medicine
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (431)
  • Anesthesia (99)
  • Cardiovascular Medicine (943)
  • Dentistry and Oral Medicine (178)
  • Dermatology (109)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (420)
  • Epidemiology (8971)
  • Forensic Medicine (4)
  • Gastroenterology (418)
  • Genetic and Genomic Medicine (1938)
  • Geriatric Medicine (190)
  • Health Economics (400)
  • Health Informatics (1323)
  • Health Policy (657)
  • Health Systems and Quality Improvement (517)
  • Hematology (212)
  • HIV/AIDS (416)
  • Infectious Diseases (except HIV/AIDS) (10772)
  • Intensive Care and Critical Care Medicine (571)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (221)
  • Neurology (1819)
  • Nursing (108)
  • Nutrition (271)
  • Obstetrics and Gynecology (351)
  • Occupational and Environmental Health (469)
  • Oncology (992)
  • Ophthalmology (296)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (576)
  • Pharmacology and Therapeutics (275)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1892)
  • Public and Global Health (4111)
  • Radiology and Imaging (674)
  • Rehabilitation Medicine and Physical Therapy (364)
  • Respiratory Medicine (548)
  • Rheumatology (224)
  • Sexual and Reproductive Health (190)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (38)
  • Transplantation (109)
  • Urology (80)